The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL).
Don M. Benson
Research Funding - Gilead Sciences
Brad S. Kahl
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Richard R. Furman
Research Funding - Gilead Sciences
Jennifer R. Brown
No relevant relationships to disclose
Nina D. Wagner-Johnston
No relevant relationships to disclose
Steven E. Coutre
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Stephen Edward Forbes Spurgeon
Research Funding - Gilead Sciences
John C. Byrd
Research Funding - Gilead Sciences
John Leonard
Consultant or Advisory Role - Gilead Sciences
Sissy Peterman
Employment or Leadership Position - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Yoonjin Cho
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Wayne R. Godfrey
Employment or Leadership Position - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences